Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 15/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 16/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 13/20 | 0.37 |
| ▸ | MMP1 | P03956 | 11/20 | 0.37 |
| ▸ | MMP7 | P09237 | 9/20 | 0.37 |
| ▸ | MMP9 | P14780 | 5/20 | 0.36 |
| ▸ | MMP8 | P22894 | 5/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772015 | 0.71 | MMP2 (0.47) | MMP13ADAMTS4MMP2MMP3MMP1 | |
| SCHEMBL6767990 | 0.70 | MMP2 (0.45) | MMP13ADAMTS4MMP2MMP3MMP1 | |
| SCHEMBL6773324 | 0.69 | HSD11B1 (0.39) | HSD11B1GAAKMT2AMMP13ADAMTS4 | |
| SCHEMBL28410070 | 0.59 | KMT2A (0.57) | GAAKMT2A | |
| SCHEMBL6773472 | 0.58 | MMP2 (0.53) | MMP13ADAMTS4MMP2MMP3MMP1 | |
| SCHEMBL18292532 | 0.58 | POLB (0.72) | KMT2A | |
| SCHEMBL8712240 | 0.58 | GAA (1.00) | GAAKMT2A | |
| SCHEMBL7497507 | 0.57 | MMP2 (0.55) | MMP13ADAMTS4MMP2MMP3MMP1 | |
| SCHEMBL6774033 | 0.57 | MMP2 (0.55) | MMP13ADAMTS4MMP2MMP3MMP1 | |
| SCHEMBL7762300 | 0.57 | POLB (0.48) | GAAMMP13ADAMTS4MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762198-B2 | SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID | THE PROCTER & GAMBLE COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | ADAM9, ADAM17, ADAM8 | HSD11B1 503/4885GAA 89/4885KMT2A 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.